Eubelius advised Balyasny Asset Management on its participation in the oversubscribed $125 million Series A financing round of Coultreon Biopharma (formerly Onco3R Therapeutics). Coultreon Biopharma is a biotechnology company developing best-in-class therapies in immunology. Coultreon’s lead program, COL-5671, is a potential first-in-class, oral once-daily SIK3 inhibitor currently in Phase 1 studies, with plans to advance into Phase 2 trials in psoriasis and ulcerative colitis. The financing was led by Sofinnova Investments, with Forbion and Novo Holdings as co-leads, joined by Galapagos, Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund and Finchley Healthcare Ventures.
The Eubelius team advising Balyasny Asset Management consisted of partner Joris De Wolf and associate Thijs Keuleers.
For more information on the transaction and Coultreon’s development plans, please refer to the company’s press release.
